RB1 and breast carcinoma: In 2017, Gavressa et al. found that the p53 mediated sensitivity of breast cancer cells to chemotherapeutic agents appears to be driven mostly by pRB, and that using agents that enhance RB phosphorylation might possibly increase the chemosensitivity of breast cancer cells.